Mixed Dyslipidemias (DBCOND0073163)

Identifiers

Synonyms

Mixed Hyperlipidaemia / Mixed Dyslipidemia / Mixed Hyperlipidemia / Mixed hypercholesterolemia / Broad- or floating-betalipoproteinemia / Type V hyperlipidaemia / Type V hyperlipidemia / Type V lipidaemia / Type V lipidemia / Hyperlipoproteinemia Type V / Type V hyperlipoproteinemia / Fredrickson Type V lipidemia / Fredrickson Type V lipidaemia / Type V hyperlipoproteinaemia

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Amlodipine	A calcium channel blocker used to treat hypertension and angina.	Carbonic anhydrase 1target Cytochrome P450 3A4enzyme Voltage-dependent L-type calcium channel subunit alpha-1Ctarget Cytochrome P450 1A1enzyme Cytochrome P450 2B6enzyme Voltage-dependent N-type calcium channel subunit alpha-1Btarget Voltage-dependent L-type calcium channel subunit beta-1target Voltage-dependent calcium channel subunit alpha-2/delta-3target Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme Sphingomyelin phosphodiesterasetarget Voltage-dependent T-type calcium channel subunit alpha-1Itarget Voltage-dependent N-type calcium channeltarget Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme Voltage-dependent calcium channel subunit alpha-2/delta-1target
Atorvastatin	An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.	3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget Cytochrome P450 3A4enzyme Dipeptidyl peptidase 4target Cytochrome P450 2D6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1A2transporter Solute carrier organic anion transporter family member 1B1transporter ATP-binding cassette sub-family C member 4transporter ATP-binding cassette sub-family C member 5transporter Multidrug resistance-associated protein 1transporter Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme Aryl hydrocarbon receptortarget Solute carrier organic anion transporter family member 2B1transporter Solute carrier organic anion transporter family member 1B3transporter UDP-glucuronosyltransferase 1A1enzyme UDP-glucuronosyltransferase 1A3enzyme ATP-binding cassette sub-family C member 2transporter Bile salt export pumptransporter Albumincarrier Histone deacetylase 2target Nuclear receptor subfamily 1 group I member 3target
Fenofibrate	A peroxisome proliferator receptor alpha activator used to lower LDL-C, total-C, triglycerides, and Apo B, while increasing HDL-C in hypercholesterolemia, dyslipidemia, and hypertriglyceridemia.	Peroxisome proliferator-activated receptor alphatarget Matrix metalloproteinase-25target Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Nuclear receptor subfamily 1 group I member 2target UDP-glucuronosyltransferase 1A9enzyme Bile salt export pumptransporter Albumincarrier Cytochrome P450 2C19enzyme Cytochrome P450 2A6enzyme Liver carboxylesterase 1enzyme Carbonyl reductase [NADPH] 1enzyme Aldo-keto reductase family 1 member C1enzyme Aldo-keto reductase family 1 member C2enzyme Aldo-keto reductase family 1 member C3enzyme Aldo-keto reductase family 1 member B1enzyme
Fenofibric acid	A fibrate used to treat severe hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia.	Peroxisome proliferator-activated receptor alphatarget Matrix metalloproteinase-25target Peroxisome proliferator-activated receptor gammatarget Peroxisome proliferator-activated receptor deltatarget Nuclear receptor subfamily 1 group I member 2target Fatty acid-binding protein, livertarget
Fluvastatin	An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.	3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget Cytochrome P450 2C9enzyme Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2C19enzyme Cytochrome P450 1A1enzyme Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier organic anion transporter family member 2B1transporter Solute carrier family 15 member 1transporter Cytochrome P450 3A5enzyme UDP-glucuronosyltransferase 1A1enzyme UDP-glucuronosyltransferase 1A3enzyme UDP-glucuronosyltransferase 2B7enzyme ATP-binding cassette sub-family C member 2transporter Cytochrome P450 2B6enzyme Histone deacetylase 2target
Inclisiran	A PCSK9-targeting short interfering RNA (siRNA) that lowers plasma LDL-cholesterol levels.	Proprotein convertase subtilisin/kexin type 9target
Lovastatin	An HMG-CoA reductase inhibitor used to lower LDL cholesterol and reduce the risk of cardiovascular disease and associated conditions, including myocardial infarction and stroke.	3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Integrin alpha-Ltarget Histone deacetylase 2target Serum paraoxonase/lactonase 3enzyme ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1A2transporter Solute carrier organic anion transporter family member 1B1transporter UDP-glucuronosyltransferase 1A1enzyme UDP-glucuronosyltransferase 1A3enzyme UDP-glucuronosyltransferase 2B7enzyme ATP-binding cassette sub-family C member 2transporter Bile salt export pumptransporter Albumincarrier Cytochrome P450 2C19enzyme Solute carrier organic anion transporter family member 2B1transporter Solute carrier organic anion transporter family member 1B3transporter
Niacin	A B vitamin used to treat hypertriglyceridemia and pellagra.	Hydroxycarboxylic acid receptor 2target Nicotinamide N-methyltransferasetarget Nicotinate-nucleotide pyrophosphorylase [carboxylating]target Hydroxycarboxylic acid receptor 3target Organic cation/carnitine transporter 2transporter Solute carrier organic anion transporter family member 2B1transporter Monocarboxylate transporter 1transporter Cytochrome P450 2D6enzyme Sodium-coupled monocarboxylate transporter 1transporter Monocarboxylate transporter 4transporter Thyroxine-binding globulincarrier Cytochrome P450 3A4enzyme Cytochrome P450 2E1enzyme Diacylglycerol O-acyltransferase 2target
Pitavastatin	An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.	Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter UDP-glucuronosyltransferase 2B7enzyme UDP-glucuronosyltransferase 1A3enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C8enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget Solute carrier organic anion transporter family member 2B1transporter Hepatic sodium/bile acid cotransportertransporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 2transporter Albumincarrier Alpha-1-acid glycoprotein 1carrier Bile salt export pumptransporter Integrin alpha-Ltarget
Pravastatin	An HMG-CoA reductase inhibitor used to lower lipid levels and to reduce the risk of cardiovascular events, including myocardial infarction and stroke.	3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget Solute carrier organic anion transporter family member 2B1transporter ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1A2transporter Solute carrier family 22 member 6transporter Organic anion transporter 3transporter ATP-binding cassette sub-family C member 2transporter Solute carrier family 22 member 11transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 7transporter Solute carrier organic anion transporter family member 1B1transporter Monocarboxylate transporter 1transporter Bile salt export pumptransporter Solute carrier organic anion transporter family member 1B3transporter Histone deacetylase 2target
Rosuvastatin	An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.	3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget Cytochrome P450 2C9enzyme ATP-binding cassette sub-family C member 4transporter Solute carrier organic anion transporter family member 1A2transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier organic anion transporter family member 2B1transporter Cystine/glutamate transportertransporter Solute carrier organic anion transporter family member 1B1transporter Bile salt export pumptransporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Albumincarrier ATP-binding cassette sub-family C member 2transporter Organic anion transporter 3transporter Hepatic sodium/bile acid cotransportertransporter Integrin alpha-Ltarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00479388	Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)	Atorvastatin Laropiprant Niacin Simvastatin	treatment	3	completed
NCT03648788	A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe	No drug interventions	Not Available	Not Available	unknown_status
NCT00465088	An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)	Atorvastatin Niacin Simvastatin	treatment	3	completed
NCT02275156	Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab	Evolocumab	treatment	1	completed
NCT02548832	Bezafibrate Plus Berberine in Mixed Dyslipidemia	Berberine Bezafibrate	treatment	3	completed
NCT00136799	Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia	Fluvastatin	treatment	3	completed
NCT00171236	Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia	Fluvastatin	treatment	3	completed
NCT01228019	Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)	Laropiprant Niacin	Not Available	Not Available	terminated
NCT01879319	Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen	Evolocumab	treatment	3	completed
NCT06314919	A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib	No drug interventions	Not Available	Not Available	recruiting
NCT06386419	A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia	Inclisiran	treatment	4	not_yet_recruiting
NCT00300430	Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.	Atorvastatin Fenofibric acid Rosuvastatin Simvastatin	treatment	3	completed
NCT00491530	A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia	Atorvastatin Fenofibric acid Rosuvastatin Simvastatin	treatment	3	completed
NCT05118230	Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia	No drug interventions	Not Available	Not Available	completed
NCT00300482	Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood	Fenofibric acid Rosuvastatin	treatment	3	completed
NCT00479882	MK-0524B Lipid Study (MK-0524B-063)	Laropiprant MK-0524B Niacin Simvastatin	treatment	3	completed
NCT01256476	Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia	Pitavastatin Pravastatin	treatment	4	completed
NCT00487591	An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia	Omega-3-acid ethyl esters Simvastatin	Not Available	Not Available	completed
NCT05399992	Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD	No drug interventions	Not Available	Not Available	recruiting
NCT04998201	Study of ARO-APOC3 in Adults With Mixed Dyslipidemia	ARO-APOC3	treatment	2	completed
NCT00678743	An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin	Omega-3-acid ethyl esters Simvastatin	treatment	4	unknown_status
NCT02739984	Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia	Evolocumab	treatment	3	completed
NCT05546398	SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®	Bempedoic acid Ezetimibe	Not Available	Not Available	completed
NCT01335997	Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)	Laropiprant MK-0524B Niacin Simvastatin	treatment	3	terminated
NCT01849497	Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen	Evolocumab	treatment	3	completed
NCT04832971	Study of ARO-ANG3 in Adults With Mixed Dyslipidemia	ARO-ANG3	treatment	2	active_not_recruiting
NCT00300456	Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood	Fenofibric acid Simvastatin	treatment	3	completed
NCT01274559	Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)	Laropiprant Niacin	treatment	3	terminated
NCT05400317	A Study to Evaluate the Efficacy and Safety of AD-218	No drug interventions	treatment	3	recruiting
NCT00639158	Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood	Atorvastatin Ezetimibe Fenofibric acid	treatment	3	completed
NCT06497127	A Study in Patients With Mixed Dyslipidemia	No drug interventions	treatment	2	not_yet_recruiting
NCT06204380	An Observational Study on the Identification of Prescription Patterns of STAFEN Cap	No drug interventions	Not Available	Not Available	recruiting
NCT04579367	Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia	Bempedoic acid Ezetimibe	Not Available	Not Available	recruiting
NCT00300469	Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood	Atorvastatin Fenofibric acid	treatment	3	completed
NCT00309712	Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study	Fenofibrate Simvastatin	treatment	Not Available	completed
NCT03433755	Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia	Evolocumab	treatment	3	terminated
NCT05798390	Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia	Bempedoic acid Ezetimibe	Not Available	Not Available	withdrawn
NCT02262143	Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia	Fenofibrate Rosuvastatin	treatment	3	completed
NCT04643093	Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia	Ezetimibe Pitavastatin	treatment	3	completed